NTRK1 and neoplasm: Previous studies identified C-1311 as a multitargeted compound, which blocks activity of topoisomerase II [13], HIF-1α/VEGF signalling, tumour angiogenesis [14], and FLT3 receptor tyrosine kinase FLT3 [15].